Comment on

• The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.

  Middleton ET, Steel SA, Aye M, Doherty SM. Middleton ET, et al. J Bone Miner Res. 2010 Mar;25(3):455-62. doi: 10.1359/jbmr.090821. J Bone Miner Res. 2010. PMID: 20201000 Clinical Trial.
• Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: Matrix incorporation of strontium is accompanied by changes in mineralization and microstructure.

  Busse B, Jobke B, Hahn M, Priemel M, Niecke M, Seitz S, Zustin J, Semler J, Amling M. Busse B, et al. Acta Biomater. 2010 Dec;6(12):4513-21. doi: 10.1016/j.actbio.2010.07.019. Epub 2010 Jul 21. Acta Biomater. 2010. PMID: 20654744 Clinical Trial.
• The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years.

  Middleton ET, Steel SA, Aye M, Doherty SM. Middleton ET, et al. Osteoporos Int. 2012 Jan;23(1):295-303. doi: 10.1007/s00198-011-1547-8. Epub 2011 Jan 28. Osteoporos Int. 2012. PMID: 21274515 Clinical Trial.